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Summary: Biochemical and pharmacological investigations 
about the effect of the antidepressant drug viloxazine (Viva-
Ian®) on catecholamine metabolism in rats led to the follow-
ing results: 
1. Viloxazine exerts a dose and time dependent inhibition of 
monoamine oxidase activity of brain and liver mitochondrial 
fraction and tissue homogenates of hypothalamus, heart, 
liver, and adrenal glands, both in vitro and after oral and 
parenteral administration in vivo. 
') Present address: 2. Medizinische K l i n i k , K l i n i k u m Mannheim 
der Universitat Heidelberg, Mannhe im (Federal Republic of Ger-
many). 
2. Consequently, an increase in catecholamine concentra-
tions in brain of rats could be observed after pretrealment 
with viloxazine. In addition brain serotonin concentrations 
rose and 5-hydroxy-indoleacetic acid was diminished. 
3. However, characterization of inhibition of monoamine ox-
idase activity by viloxazine in vitro revealed: Compared to 
the specific inhibitors clorgyline for MAO-A- and pargyline 
for MAO-B-activity, viloxazine was a very weak inhibitor 
both for MAO-A and MAO-B in vitro. The type of inhibition 
was competitive and reversible. 
4. From the presented results and the results obtained by 
other laboratories it is concluded that inhibition of mono-
amine oxidase activity by viloxazine, although clearly de-
monstrated in animal experiments, may not be the only 
mechanism for an antidepressant action of the drug in man. 
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Zusammenfassung: Hemmung der Monoaminoxidase durch 
Viloxazin bei Ratten 
Biochemische and pharmakologische Untersuehungen tiber 
die Wirkung des Antidepressivums Viloxazin (Vivalan®) auf 
den Kateeholamin-Stoffweehsel von Ratten Juhrten zu fol-
genden Ergebnissen: 
1. Viloxazin verursachte eine dosis- und zeitabhdngige 
Hemmung der Aktivitdt der Monoaminoxydase der Mito-
chondrienfraktion von Gehirn und Leber sowie in Gewebe-
homogenaten des Hypothalamus, des Herzens, der Leber 
und der Nebennieren von Ratten, so wo hi in vitro, a Is auch in 
vivo, naeh oraler oder parentaler Applikation des Pharma-
kons. 
2. Als Folge dieser Hemmung der Monoaminoxydase stei-
gen die Konzentrationen von Kateeholaminen und von Sero-
tonin im Gehirn an, wahrend die 5-Hydroxyindolessigsdure, 
das desaminierte Produkt von Serotonin, signijikant vermin-
den wurde. 
3. Die Charakterisierung des Hemmtyps von Viloxazin in 
vitro ergab eine kompetitive und reversible Art der Hem-
mung. Viloxazin wurde dariiber hinaus als schwacher 
Hemmstoff der Monoaminoxydase A und B erkannt bei 
Vergleiehsuntersuchungen mil Clorgylin als Hemmstoff der 
A-Form der Monoaminoxydase und Pargylin als Hemmstoff 
der B-Form der Monoaminoxydase\ 
4. Die vorliegenden Ergebnisse und die Untersuehungen in 
anderen Laboratorien erlauben jedoch die Schlufifolgerung, 
dafi trotz nachgewiesener Hemmung der Monoaminoxydase 
durch Viloxazin im Tierexperiment noch andere Mechanis-
men zur antidepressiven Wirkung des Pharmakons beim 
Menschen beitragen. 
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1. Introduction 
It is generally accepted that cl inically used antidepressant 
drugs may exert their pharmacological effects mainly by in-
hibition of the reuptake of noradrenaline and serotonin (tri-
cyclic antidepressant drugs) or by inhibition of monoamine 
oxidase (MAO-inhibi tors) , thereby increasing the postsynap-
tic concentration of these amines and consequently poten-
tiating their transmitter functions. These prominent phar-
macological activities of antidepressant drugs are probably 
related to their therapeutic actions [2, 4, 13]. In recent years 
it was observed that persistent high postsynaptic concentra-
tions of noradrenaline or serotonin can lead to a down regu-
lation of ^-adrenergic receptors or serotoninergic receptors 
(for review see [12]). In addition a blockade of alpha-
adrenergic receptors or histamine receptors by antidepres-
sant drugs has been described [6, 15]. Concerning the mech-
anisms of recently introduced antidepressant drugs it is of 
interest to classify such drugs within the scheme to the cur-
rent hypothesis of their mode of action, despite several ob-
jections against a close correlation between observed bio-
chemical effects and their therapeutic action in patients. 
Therefore the a im of the present paper was to characterize 
some pharmacological effects of viloxazine (2-(2-ethoxy-
phenoxymethyl)-2,3,5,6-tetrahydro-1,4-oxazine, Vivalan® 2)) 
in experiments in rats, especially its effect of monoamine ox-
idase activity, characterizing its mode of inhibition both in 
vivo and in vitro. 
2. Methods 
: Ma le Sprague-Dawley rats (SIV 50) from Dr . Ivanovas, Kisslegg (FR 
{Germany), body weight about 150 g, were used. The animals were 
[housed in plastic cages (Makrolon®) in an air-conditioned, light-
Jdark-cycled (12 h) room, with lights on from 6 a.m. to 6 p.m., and 
|given food (Altromin®, standard diet; A l t r o m i n , Lage/Lippe, F R 
^Germany) and tap water ad l ib i tum. They received viloxazine in 
{various doses orally (stomach tube) and parenterally as indicated 
!under results. Controls were given 0.9% N a C l . Assay of monoamine 
!oxidase was performed radiometrically according to Otsuka and K o -
bayashi [12] using various substrates as described under results. In 
Jsome experiments we used preparations of mitochondria from rat 
brain [11] or rat liver [14] for assay of monoamine oxidase activity. 
Protein was determined according to the method of Bradford [3]. 
Fo r determination of catecholamines (noradrenaline, dopamine) and 
serotonin we used high pressure l iquid chromatography [1]. 
[Data were statistically evaluated, using unpaired Student's t-test. 
|Results are expressed as mean ± S . E . M . 
3. Results 
Subcutaneous injection of viloxazine (70 mg/kg) caused a 
time dependent inhibit ion of monoamine oxidase activity in 
preparations of mitochondria from rat brain (Fig. 1). Using 
serotonin or /?-phenylethylamine as substrates the maxi-
mum of inhibit ion occurred between 1 and 3 h after admin-
istration of the drug. 7 h after injection of viloxazine the 
monoamine oxidase activity was normal when compared to 
control preparations. 
Concomitantly there was a significant increase in the 
concentration of brain dopamine and noradrenaline (Fig. 2). 
The maximum of transmitter concentrations run parallel 
with the inhibit ion of monoamine oxidase activity. Investi-
gating increasing doses of viloxazine (35, 70, 105 mg/kg s.c.) 
1 h after administration revealed in a dose dependent inhibi-
Fig. 1: Inhibit ion o f monoamine oxidase in mitochondrial fraction o f hypo-
thalamus o f rats after s.c. injection o f 70 mg/kg viloxazine. Substrates: 3 H -
serotonin = 1 x I O - 8 mol/1; , 4 C-/ j -phenylethylamine = I x l O - 5 mol/1. 
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|) Manufacturer: ICI-Pharma, Plankstadt (Federal Republic of Ger-
; many). 
Fig. 2: Increase o f catecholamine concentrations in rat brain after s.c. injec-
tion o f 70 mg/kg vi loxazine groups o f 10 rats. * p < 0.05, ** p < 0.01, 
*** p < 0.005, **** p < 0.001. Left: dopamine; right: noradrenaline. 
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Fig. 3: Inhibition of the two forms of monoamine oxidase in rat brain and 
liver mitochondrial fraction 1 h after s.c. injection of increasing doses o f v i l -
oxazine. Substrates: M A O - A = 3 H-Serotonin I O - 8 mol/1, M A O - B = bra in : 
IO" 6 mol/1. liver IO" 5 mol/1. , 4 C-/?-phenylethvlamine. * p < 0.05. 
**p < 0 .01 .*** p < 0.005.**** p < 0.001. 
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Fig. 4 : Dose-response curves for inhibi t ion of monoamine oxidase from rat 
brain homogenates by specific inhibitors of M A O - A or M A O - B in compar-
ison to viloxazine. Incubation: 20 min , 37 c C Left: O . clorgyline, substrate: 
3 H-Serotonin IOr 4 mol/1: pargyline, substrate: 1 4 C-phenylethylamine IO" 6 
mol/1. Right: vi loxazine, substrate: O . 3 H-Serotonin IO" 4 mol/1: 1 4 C -
phenylethylamine IO" 6 mol/1. 
tion of monoamine oxidase in mitochondria of rat liver and 
hypothalamus using serotonin or /^phenylethylamine as 
substrates (Fig. 3). 
The effect of viloxazine after repeated administration (35 
mg/kg i.p. daily during 6 days) on monoamine oxidase activ-
ity ( M A O activity) in various organs of the rat is depicted in 
Table 1. The inhibi t ion of M A O was most pronounced in 
the rat heart, but also a significant inhibit ion of the enzymes 
could be observed in hypothalamus, liver, and adrenal gland. 
In these experiments tryptamine was used as a substrate for 
both forms of the enzyme M A O - A and M A O - B . In addition-
al experiments we prepared fractions of mitochondria from 
hypothalamus and liver after chronic treatment with vi loxa-
zine (35 mg/kg s.c. daily over a period of 8 days). In the 
brain M A O - A activity was inhibited significantly by 14%, 
M A O - B activity by 23% and in liver M A O - B activity by 9%. 
The substrates used for M A O - A was 3H-Serotonin (IO" 8 
mol/1) and for M A O - B was 1 4 C-phenylethylamin (10- 6 
mol/1). 
Table 1: Inhibition o f monoamine oxidase activity in rat tissue after s.c. injec-
tion o f 35 mg/kg viloxazine daily during 6 days. 
Controls n V i loxaz ine n Inhibi t ion 
(%) P 
Hypothalamus 1 6 2 4 ± 26 5 1264 ± 4 3 5 22 **** 
Heart 1853 Jr 106 5 1 1 6 4 ± 8 2 5 37 **** 
Live r 1 2 9 2 ± 35 6 1028 ± 3 2 5 20 **** 
Adrena l gland 1 7 1 2 ± 27 4 1266 ± 7 5 5 26 *** 
Substrate: 1 4 C-Irvptamine 10"- mol/1: x ± Sx = c p m / m i n : n = number of rats: 
p = level of significance: *** p < 0.005. **** p < 0.001. 
Analysing the results obtained with serotonin as a substrat in 
hypothalamus mitochondrial fraction according to Line-
weaver-Burk we observed a mixed type of inhibition of 
monoamine oxidase activity by viloxazine (Fig. 4). 
As a consequence of significant inhibit ion of monoamine 
oxidase activity in the brain we found increased concentra-
tions of the putative transmitters, dopamine, noradrenaline 
and serotonin after acute (Fig. 2), as well as after chronic ad-
ministration. The effect of viloxazine on noradrenaline and 
Table 3: Changes in serotonin and 5-hydroxyindoleacetic acid concentrations 
in brain of rats after oral administration of viloxazine daily over a period of 
14 days. 
Dose 
(mg/kg) 
Serotonin 5-Hydroxyindoleacetic acid 
Cone, (/ug/g) n P Cone. Gug/g) n P 
Controls 0.40 ± 0 . 0 1 10 0 . 4 9 ± 0 . 0 1 9 
35 0 . 5 8 ± 0 . 0 4 9 **** 0.41 ± 0 . 0 1 9 **** 
70 0 . 7 4 ± 0 . 0 6 10 **** 0 . 3 7 ± 0 . 0 1 10 **** 
n = number of rats: **** p < 0.005: x ± Sx-
dopamine levels was dose dependent and more marked on 
dopamine concentrations (Table 2). Also serotonin concen-
trations in brain rose significantly and dose dependent after 
s.c. injection of viloxazine. 
Chronic oral administration of increasing doses of viloxazine 
also caused an increase in brain serotonin concentrations 
and a decrease in 5-hydroxyindoleacetic acid (Table 3). 
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Fig. 5: Characterization of type of inhibi t ion of monoamineoxidase by v i l o x a : 
zine. Linevveaver-Burk plot. Substrates: 3 H-Serotonin: 1 x IO" 3 - 3 x 10~ 5 
mol/1. O n mitochondrial fraction of hypothalamus of pretreated animals 35 
mg/kg s.c. daily over a period of 8 days. • = controls. 
Table 2: Elevation in catecholamines and serotonin concentrations in brain of rats I h after s.c. injection after increasing doses of viloxazine. 
Dose 
(mg/kg) 
Dopamine Noradrenaline Serotonin 
Cone. Gug/g) n P Cone, (/ig/g) n P Cone, (ug/g) n P 
Controls 0 . 4 5 ± 0 . 0 2 10 0 . 3 9 ± 0 . 0 1 10 0 . 4 6 ± 0 . 0 4 10 
35 0 . 5 3 ± 0 . 0 3 10 (*) 0 . 4 3 ± 0 . 0 1 10 0 . 6 3 ± 0 . 0 7 10 * 
70 0.53 ± 0 . 0 3 10 * 0.43 + 0.01 10 ** 0 . 6 6 ± 0 . 0 5 10 ** 
105 0 . 5 9 ± 0 . 0 2 10 ** 0 . 4 6 ± 0 . 0 1 9 **** 0 . 7 2 ± 0 . 0 4 10 **** 
n = groups of 9-10 rats: (*)p < 0.1.*p < 0.05. ** p < 0.01. ***p < 0.005. * * " p < 0.001 :x ± S,. 
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Characterization of inhibition of the monoamine oxidase 
activity by viloxazine in vitro led to the following results: 
1. Compared to the specific inhibitors clorgyline for 
M A O - A and pargyline for M A O - B , viloxazine was a very 
weak inhibition both for M A O - A and M A O - B (Fig. 5). 
2. The type of inhibition under the in vitro conditions was 
competitive according to Lineweaver-Burk using seroto-
nin as a substrate and a mitochondrial fraction of hypo-
thalamus (Fig. 6). 
In further experiments it could be demonstrated that the 
inhibition in vitro under the same conditions as described 
in legend of Fig. 6 was reversible [9]. 
1_ mg protein min 
Vpmol SHlAA 
F i g . 6: In vitro characterization of inhibi t ion o f monoamine oxidase in mito-
chondrial fraction o f rat hypothalamus by viloxazine. K = 9.7 x IO" 5 mol/1; 
K = 1.8 x IO" 4 mol/1. 
4. Discussion 
The results presented in this paper are in agreement with the 
assumption that viloxazine is capable to inhibit the mono-
amine oxydase activity of rat tissue in a dose dependent 
manner, after acute or chronic oral or parenteral administra-
tion of the drug. Moreover, the maximum of the inhibitory 
effect on monoamine oxidase activity runs parallel with an 
increase in rat brain catecholamines (dopamine, noradrena-
line) and serotonin. These results are in disagreement with 
the conclusion of Lippman and Pugsley [10] that viloxazine 
does not inhibit monoamine oxidase in mice. However, 
these authors observed a potentiation of the L-dopa behav-
ioral syndrome in the mouse by viloxazine and also an ant-
agonism against reserpine induced ptosis and hypothermia 
in the same species. Since viloxazine also exerts some effects 
on uptake of catecholamines, like imipramine, the authors 
concluded, that uptake inhibition might be the reason for 
the observed drug action. In addition Greenwood [9] denied 
a significant inhibit ion by viloxazine on monoamine inhibi-
tory oxidase activity, although he used only tyramine as sub-
strate in his in vitro experiments and interestingly in vivo he 
could observe a short lasting increase in brain catechola-
mines and serotonin after injection of a single dose of viloxa-
zine. Moreover, L ippman and Pugsley [10] noticed a de-
crease in concentrations of deaminated metabolites from 3 H -
noradrenaline in rat hypothalamus after administration of 
20 mg/kg i.p. viloxazine. This is in agreement with the sig-
nificant inhibit ion of monoamine oxidase after administra-
tion of viloxazine in a single dose or repeated doses, not only 
in brain, but also in other organs reported under results. We 
could also demonstrate that viloxazine in vivo (Fig. 1/Fig. 3) 
and in vitro (Fig. 5) can inhibit monoamine oxidase in the A 
and B form. In addition the in vitro characterization of 
M A O - i n h i b i t i o n by viloxazine resulted in a competitive and 
reversible type of inhibit ion (Fig. 6). However, in vivo we 
observed a mixed type of inhibit ion of monoamine oxidase 
by viloxazine after chronic administration (Fig. 4). 
This difference might be due to the formation of an active 
metabolite of viloxazine, which could shift the type of inh i -
bition observed in vitro. In agreement with this assumption 
we observed a biphasic inhibit ion of liver monoamine oxi -
dase occurring with two peaks of inhibi t ion 1 and 5 h after 
70 mg/kg s.c. viloxazine in a single dose [11]. 
Despite the high concentration necessary for viloxazine to 
inhibit the monoamine oxidase completely in vitro, when 
compared to clorgyline ( M A O - A ) and pargyline ( M A O - B , 
Fig. 5), and the high doses used in vitro, it is likely that inhi -
bition of monoamine oxidase of both forms in vivo makes a 
contribution to the antidepressant effect of the drug in pa-
tients. In line with this hypothesis a long lasting half life of 
viloxazine was reported in the liquor cerebrospinalis of de-
pressive patients treated with viloxazine [5]. 
In addition a significant decrease in deaminated metabolites 
of noradrenaline and dopamine in urine of healthy volun-
teers after application of viloxazine was reported by G o o d -
win et al . [7] (see also [4]). Since monoamine oxidase in hu-
man brain might exist in form A and B, our results are de-
monstrating an inhibit ion of both forms by viloxazine 
could be of interest for the therapeutic action of the drug in 
man. 
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